New Abecma (ide-cel) CAR T FDA Approval in Myeloma - HealthTree for Multiple Myeloma
[logo] HealthTree Foundation
more_vert
close
person Sign In / Create Account

The New Abecma (ide-cel) CAR T FDA Approval in Multiple Myeloma with Dr. Noopur Raje, Mass General

The New Abecma (ide-cel) CAR T FDA Approval in Multiple Myeloma with Dr. Noopur Raje, Mass General image

The New Abecma (ide-cel) CAR T FDA Approval in Multiple Myeloma with Dr. Noopur Raje, Mass General

Podcast
event Apr 16, 2021 / 11:00AM MDT
link icon facebook logo X logo linkedin logo reddit logo email icon

Event Description

Noopur Raje, MD
Massachusetts General Hospital
Interview Date: April 16, 2021

The door to a new era of immunotherapy has CAR T therapy in multiple myeloma has been opened with the recent approval of Abecma (ide-cel) by Bristol Myers Squibb. Dr. Noopur Raje shares more about the history of CAR T therapy, its potential use in multiple myeloma, who can obtain the treatment and more about the CAR T process. As one of the initial investigators on four years of clinical trials for this treatment, Dr. Raje provides in-depth information about this groundbreaking new therapy. 

To find an open site for Abecma CAR T treatment, click here

Thanks to our episode sponsor

Schedule & Agenda

Event panelist Dr. Noopur Raje & Jenny Ahlstrom
11:00 AM
Discussion
Dr. Noopur Raje & Jenny Ahlstrom

Speakers & Moderators

The panelist Noopur Raje, MD
Noopur Raje, MD

Noopur Raje, MD, is director of the Center for Multiple Myeloma at Massachusetts General Hospital. She is also Associate Professor of Medicine at Harvard Medical School. Her primary focus is treating patients with multiple myeloma and related plasma cell disorders. Dr. Raje leads a dedicated clinical team engaged in investigator-initiated, multi-center national and international clinical trials, all aimed at developing new promising therapies for multiple myeloma. Her laboratory efforts are focused on identifying cellular signaling pathways that contribute to the survival and proliferation of myeloma cells in the bone environment for which targeting may result in improved therapeutic outcomes.

Read Bio
The panelist Jennifer Ahlstrom
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of the HealthTree Foundation.

Read Bio

Have Any Questions?

Thank you for your interest in the event. If you have any questions, we would love to help!

Feel free to give us a call or send us a message below.

support

Get In Touch With Us

phone

1-800-709-1113

email

Support@healthtree.org

Thanks to our sponsors:
Johnson and Johnson logo
Sanofi logo
Pfizer logo
GSK logo
Regeneron logo
All HealthTree resources available anywhere, anytime
Download our App
Download iOS App Download Android App
iphone app mockup
newsletter icon

Get the Latest Multiple Myeloma Updates, Delivered to You.

By subscribing to the HealthTree newsletter, you'll receive the latest research, treatment updates, and expert insights to help you navigate your health.